In studies that demonstrated the utility of SGLT2 inhibitors in HFpEF, cardiac imaging was required in the protocols but was limited to measurement of left atrial size or LV mass by echocardiography or cardiac magnetic resonance (CMR).3,4 Potentially, more refined phenotyping based on strain imaging and indices of LV diastolic function may be used to optimize patient selection for SGLT2 inhibitor and other HF drugs and should be explored in future studies. Here, SLC5A2 is linked to hydrops fetalis.